Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05191472 | Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies | terminated | Phase 2 | 3 | Alfred Chung, MDOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 26 | CRISPR Therapeutics AGINDUSTRY | 4 | Jan 8, 2025 | clinicaltrials |
| NCT04305444 | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | terminated | Phase 2 | 55 | Zhejiang DTRM BiopharmaINDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04502446 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | terminated | Phase 1 | 49 | CRISPR Therapeutics AGINDUSTRY | 3 | Jan 8, 2025 | clinicaltrials |
| NCT05205161 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | terminated | Phase 1 | 7 | AstraZenecaINDUSTRY | 7 | Jan 7, 2025 | clinicaltrials |
| NCT04083170 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers | terminated | Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03768505 | Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) | terminated | Phase 2 | 169 | MEI Pharma, Inc.INDUSTRY | 14 | Dec 31, 2024 | clinicaltrials |
| NCT03582033 | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma | terminated | Phase 1 | 83 | Seagen Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02612311 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia(UNITY-CLL) | terminated | Phase 3 | 603 | TG Therapeutics, Inc.INDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | terminated | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05276622 | Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)(PaCE-MM) | terminated | — | 64 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-4) | terminated | Phase 3 | 551 | BayerINDUSTRY | 35 | Dec 11, 2024 | clinicaltrials |
| NCT05350163 | T-cell Receptor α/β Depleted Donor Lymphocyte Infusion | terminated | Phase 1 | 11 | Guenther KoehneOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT04340154 | Study of Sequential CAR-T Cell Treating Leukemia Children | terminated | Phase 2 | 81 | Beijing Boren HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)(PANAMA) | terminated | Phase 1 | 60 | Karyopharm Therapeutics IncINDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT03890289 | Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma(GAUDEALIS) | terminated | Phase 2 | 5 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03648372 | A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System | terminated | Phase 1 / Phase 2 | 109 | TakedaINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05032599 | Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia | terminated | Phase 1 | 19 | Beijing Boren HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03804424 | 64Cu-LLP2A for Imaging Multiple Myeloma | terminated | Early Phase 1 | 10 | Washington University School of MedicineOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05113342 | Descartes-25 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 9 | Cartesian TherapeuticsINDUSTRY | 2 | Nov 12, 2024 | clinicaltrials |
| NCT04762875 | MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies | terminated | Phase 2 | 7 | EnsomaINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT04745832 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | terminated | Phase 3 | 82 | MEI Pharma, Inc.INDUSTRY | 19 | Nov 4, 2024 | clinicaltrials |
| NCT03870451 | Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma | terminated | N/A | 18 | Wake Forest University Health SciencesOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT05289492 | Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 16 | iTeos TherapeuticsINDUSTRY | 4 | Oct 26, 2024 | clinicaltrials |
| NCT03311126 | Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma | terminated | Phase 2 | 21 | University of Wisconsin, MadisonOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | terminated | Phase 1 / Phase 2 | 46 | GenmabINDUSTRY | 5 | Oct 24, 2024 | clinicaltrials |
| NCT04860466 | A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 | 9 | CelgeneINDUSTRY | 4 | Oct 16, 2024 | clinicaltrials |
| NCT03710915 | A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 3 | HitGen Inc.INDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT04271930 | Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes | terminated | N/A | 24 | Medical College of WisconsinOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT04816526 | Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | terminated | Phase 2 | 13 | Cartesian TherapeuticsINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT05315713 | An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 8 | Hoffmann-La RocheINDUSTRY | 6 | Oct 4, 2024 | clinicaltrials |
| NCT05971056 | Providing Cancer Care Closer to Home for Patients With Multiple Myeloma | terminated | N/A | 3 | Washington University School of MedicineOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT06625359 | High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma | terminated | Phase 2 | 17 | Seoul National University HospitalOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT04431635 | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | terminated | Phase 1 | 6 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02099539 | QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 19 | Altor BioScienceINDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT02509039 | A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 1 | 15 | CelgeneINDUSTRY | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03136497 | A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 1 | 10 | Hackensack Meridian HealthOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT02002598 | Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 23 | Suzanne Lentzsch, MDOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | terminated | Phase 1 | 7 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04659044 | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 3 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05094206 | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies | terminated | Phase 1 | 4 | Medical College of WisconsinOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02978235 | A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma | terminated | Phase 1 | 11 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT04036461 | A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 47 | CelgeneINDUSTRY | 5 | Aug 30, 2024 | clinicaltrials |
| NCT05219513 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 1 | 53 | Hoffmann-La RocheINDUSTRY | 6 | Aug 23, 2024 | clinicaltrials |
| NCT01998035 | Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | terminated | Phase 1 / Phase 2 | 58 | Columbia UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03743246 | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | terminated | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 6 | Aug 15, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 15, 2025source: clinicaltrials